Technology · Semiconductor Equipment & Materials · TSE · Japan
¥38040.00+2.12%
Market cap ¥3.41TNext earnings 2026-10-30Updated Oct 24, 2026 · valuation updating
Our verdict
No fair value
We are missing the financial data our models need for this company. It will appear once the data arrives.
Not valued: there are no financial statements on file yet.
ACCE opinionLasertec Corporation (6920.T)
Fair value
Not available
ACCE price target
¥34954
Rating
Not rated
Horizon
12 months
ACCE price target published on 22 Oct 2026, 16:00 CEST.
Price used: ¥38040 at the close on 23 Oct 2026, 08:30 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
45
out of 100
P/E
43.2x
forward 34.8x
1-year return
+81.8%
Dividend yield
1.13%
Lasertec Corporation in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Lasertec makes the actinic EUV mask inspection tools that chipmakers use to check photomasks for defects before they reach the wafer fab, and it is the only supplier of that equipment at production scale. Its moat is that position: the tools are hard to replicate, customers qualify them over long cycles, and the installed base feeds recurring service revenue. The near-term story is EUV adoption at more fabs and the move to High-NA lithography, which needs new mask inspection capability, though that demand arrives unevenly and FY revenue fell 26.3% on lumpy order timing. The stock trades at 46.1x trailing and 34.1x forward earnings against a 44.4% operating margin and 33.9% ROE, so the market is pricing a recovery in orders rather than the current top line. For a portfolio manager, the question is whether the order cadence in the next two or three quarters supports that multiple, which is worth a deeper look at the backlog and customer capex guidance.